Androgen Receptor Variant 7 (AR-V7) Protein Detection in Circulating Tumor Cells by Immunocytostaining

Area of Science:

• Oncology
• Molecular Biology
• Precision Medicine

Background:

• Precision medicine in prostate cancer drug development focuses on patient-specific molecular alterations.
• Liquid biopsies offer a less invasive alternative to tissue samples for tracking cancer evolution.
• Androgen receptor variants, particularly AR-V7, are linked to castrate-resistant prostate cancer (CRPC) and treatment resistance.

Purpose of the Study:

• To explore the utility of detecting androgen receptor variant 7 (AR-V7) protein in circulating tumor cells (CTCs).
• To establish a method for AR-V7 protein detection in CTCs for improved prostate cancer prognostication.
• To investigate the complementary roles of transcript and protein detection for AR-V7 biomarker sensitivity and specificity.

Main Methods:

• Development and application of immunocytostaining for AR-V7 protein detection in CTCs.
• Utilizing liquid biopsies for longitudinal characterization of cancer cell biology.
• Correlating AR-V7 expression and localization with CRPC development and progression.

Main Results:

• AR-V7 protein is detectable in CTCs.
• Nuclear localization of AR-V7 protein in CTCs is a key indicator of its activity and prognostic value.
• Combined transcript and protein detection may enhance biomarker accuracy for CRPC.

Conclusions:

• Immunocytostaining provides a method for AR-V7 protein detection in CTCs.
• AR-V7 protein detection in CTCs can serve as a valuable biomarker for poor prognosis in prostate cancer.
• This approach supports the advancement of precision medicine strategies for managing CRPC.